^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LZM-005

    i
    Other names: LZM-005, LZM005
    Company:
    Livzon Pharma
    Drug class:
    HER2 inhibitor
    Related drugs:
    over1year
    Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. (PubMed, NPJ Breast Cancer)
    Here we report a phase I study that evaluated the safety, activity, and biomarkers of LZM005, a HER2 antibody, used as a monotherapy or in combination with trastuzumab plus docetaxel in patients with HER2-positive MBC. Biomarker analysis showed that chromatin remodeling genes KMT2B and BRWD1 were associated with better progression-free survival. LZM005 is well tolerated and shows potent activity in patients with HER2-positive MBC.
    P1 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR positive
    |
    Herceptin (trastuzumab) • docetaxel • LZM-005